US stock index futures signaled a slightly higher open, with European stocks boosted early in the day after Apple smashed analyst expectations.» Read More
At the J.P. Morgan Healthcare Conference, executives name the CEOs they'd most like to replace.
Amgen Inc. rose $1.19 or. 8 percent, to $153.11. Biogen Idec rose $2.82 or. 8 percent, to $342.70. Celgene Corp. rose $1.77 or 1.5 percent, to $120.04.
Amgen Inc. fell $3.24 or 2.1 percent, to $151.92. Biogen Idec fell $8.87 or 2.5 percent, to $339.88. Celgene Corp. fell $2.83 or 2.3 percent, to $118.27.
SAN FRANCISCO/ WASHINGTON Jan 15- U.S. healthcare executives say Obamacare is likely here to stay, despite repeated calls from Republican lawmakers for repeal of the 2010 law aimed at providing health coverage for millions of uninsured Americans. Top executives who gathered in San Francisco this week for the annual J.P. Morgan Healthcare conference, say that...
Amgen Inc. fell $2.75 or 1.8 percent, to $152.41. Biogen Idec fell $4.64 or 1.3 percent, to $344.11. Celgene Corp. fell $3.28 or 2.7 percent, to $117.82.
Amgen Inc. fell $1.45 or. 9 percent, to $153.71. Biogen Idec fell $4.30 or 1.2 percent, to $344.45. Celgene Corp. fell $1.82 or 1.5 percent, to $119.28.
Healthcare executives talk about their weekend activities.
Healthcare industry executives name the CEOs they'd be most willing to trade places with.
SAN FRANCISCO, Jan 15- The world's biggest drugmakers face a new reality when it comes to U.S. pricing for their products as insurers use aggressive tactics to extract steep price discounts, even for the newest medications. Big Pharma executives acknowledged the depth of change this week during public presentations and interviews with Reuters at the J.P....
Dr. George Scangos, Biogen Idec CEO, discusses new therapies in multiple sclerosis, Alzheimer's disease and pain.
The JPMorgan health care conference hadn't even officially begun when the first big piece of news of the week hit: Irish drugmaker Shire said Sunday morning it's purchasing orphan-drug company NPS Pharmaceuticals for $5.2 billion.
Biogen Idec's anti-LINGO-1, showed promise in a mid-stage study in reversing the nerve damage associated with acute optic neuritis.
*Family Dollar slips after earnings. *Brent crude holds above $51 a barrel. "Jobless claims they were about in line, maybe a little weaker than expected but the jobs market still points to jobs growth," said Peter Cardillo, chief market economist at Rockwell Global Capital in New York.
*Family Dollar falls after earnings. *Brent crude holds above $51 a barrel. "Jobless claims they were about in line, maybe a little weaker than expected but the jobs market still points to jobs growth," said Peter Cardillo, chief market economist at Rockwell Global Capital in New York.
*Family Dollar falls in premarket after earnings. *Brent crude holds above $51 a barrel. NEW YORK, Jan 8- U.S. stock index futures rose on Thursday, putting equities on track for a second day of gains after the S&P 500 snapped a five-day losing skid and ahead of data on the labor market.
Biogen is reporting positive results in its optic drug trial, reports CNBC's Meg Tirrell.
Biogen's anti-LINGO-1 showed potential in a phase 2 trial to reverse the nerve damage in an eye disorder called acute optic neuritis.
Check out which companies are making headlines after the bell Wednesday: WD-40, Brocade, Zumiez, GM & more.
On a down day in the market, Jim Cramer thinks this is the perfect time to review the silly preconceptions of 2014.
Some of Monday's midday movers: